Prentiss Smith & CO Inc Sarepta Therapeutics, Inc. Transaction History

Prentiss Smith & CO Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 15, 2019	SELL	$97.32 - $148.76 $70,265 - $107,404	-722 Closed	0 $0
Q2 2018 Jul 19, 2018	SELL	$71.74 - $153.69 $227,128 - $486,582	-3,166 Reduced 81.43%	722 $95,000
Q1 2018 Apr 20, 2018	BUY	$54.02 - $82.27 $16,854 - $25,668	312 Added 8.72%	3,888 $288,000
Q4 2017 Feb 13, 2018	SELL	$47.64 - $56.75 $14,863 - $17,706	-312 Reduced 8.02%	3,576 $199,000
Q3 2017 May 03, 2018	BUY	$35.73 - $47.15 $138,918 - $183,319	3,888	3,888 $176,000

531

84.5M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Prentiss Smith & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Prentiss Smith & CO Inc with notifications on news.